Literature DB >> 12196726

Concordance in pathological response to neoadjuvant chemotherapy between invasive and noninvasive components of primary breast carcinomas.

Kaneyuki Matsuo1, Takashi Fukutomi, Toru Watanabe, Tadashi Hasegawa, Hitoshi Tsuda, Sadako Akashi-Tanaka.   

Abstract

BACKGROUND: Invasive breast carcinomas are composed of invasive and noninvasive components in varying proportions and sometimes the two components show different histopathological responses to chemotherapy, however there has been no study as yet comparing the pathological response to chemotherapy of invasive and noninvasive components. PATIENTS AND METHODS: A consecutive series of 100 women neoadjuvant chemotherapy with doxorubicin and docetaxel every three weeks before surgery. After the chemotherapy, surgically resected specimens were studied histologically according to the criteria of the Japanese Breast Cancer Society.
RESULTS: Five cases (5/100; 5%) were determined to show Grade 3 pathological response, and 28 cases (28/100; 28%) showed Grade 2 response. There were 6 Grade 3 (6/96; 6%) and 18 Grade 2 (18/96; 19%) invasive component cases. There were 7 Grade 3 (7/82; 9%) and 18 Grade 2 (18/82; 22%) cases showing pathological response in the noninvasive component. With regard to pathological response, there was a strong correlation between the invasive and noninvasive components (p<0.001). There was also a correlation in pathological response between the invasive component and axillary lymph nodes in individual cases (p=0.02). There was no correlation between the response of the noninvasive component and axillary lymph nodes. By multivariate analysis, the overall primary tumor response was reflected by the histological response of the invasive component in the primary breast carcinoma.
CONCLUSION: We suggest that the pathological response of the invasive component of breast carcinoma should be evaluated, which might provide more accurate information for prognosis and treatment decisions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12196726     DOI: 10.1007/bf02967551

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  5 in total

1.  Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial.

Authors:  Masafumi Kurosumi; Yuichi Takatsuka; Toru Watanabe; Shigeru Imoto; Hideo Inaji; Hitoshi Tsuda; Futoshi Akiyama; Goi Sakamoto; Tadashi Ikeda; Shinzaburo Noguchi
Journal:  J Cancer Res Clin Oncol       Date:  2007-12-13       Impact factor: 4.553

2.  Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature.

Authors:  Sommer R Gunia; Mita S Patel; Eleftherios P Mamounas
Journal:  Case Rep Surg       Date:  2012-01-19

Review 3.  Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials.

Authors:  Raquel F D van la Parra; Henry M Kuerer
Journal:  Breast Cancer Res       Date:  2016-03-08       Impact factor: 6.466

4.  Is Breast Surgery Necessary for Breast Carcinoma in Complete Remission Following Neoadjuvant Chemotherapy?

Authors:  Hannah Richter; André Hennigs; Benedikt Schaefgen; Markus Hahn; Jens Uwe Blohmer; Sherko Kümmel; Thorsten Kühn; Marc Thill; Kay Friedrichs; Christof Sohn; Michael Golatta; Jörg Heil
Journal:  Geburtshilfe Frauenheilkd       Date:  2018-01-22       Impact factor: 2.915

5.  Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.

Authors:  Emma J Groen; Marieke E M van der Noordaa; Frederieke H van Duijnhoven; Jelle Wesseling; Michael Schaapveld; Gabe S Sonke; Ritse M Mann; Mette S van Ramshorst; Esther H Lips; Marie-Jeanne T F D Vrancken Peeters
Journal:  Breast Cancer Res Treat       Date:  2021-05-04       Impact factor: 4.872

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.